Trial cohorts report clinical remission (cessation of active symptoms) in 40–65% of stem cell recipients at 12 weeks, with endoscopic healing in a smaller subset (~30–40%). Comparison to biologic therapy remission rates (50–60% at 12 weeks) suggests marginal advantage, if any. Real-world outcomes from uncontrolled private clinics report higher success claims (70–80%), though robust outcome data are absent. Heterogeneity between trials complicates meta-analysis.
Fourteen registered trials are examining stem cell or MSC-derived approaches in ulcerative colitis populations worldwide. A 2022 phase II study involving 41 UC patients receiving intravenous allogeneic placental MSCs showed clinical remission rates of 61% at week 12, versus 24% in the placebo arm. Endoscopic inflammation scores improved significantly in the treatment group. However, this trial lacked a blinded design, and a subsequent meta-analysis of 9 UC stem cell trials (total n=187) reported heterogeneous outcomes with clinical remission ranging 35–68%. No phase III trial data have been published. Mechanistic studies indicate tumour necrosis factor suppression and regulatory T-cell expansion.
我是候选人吗？ → · Ulcerative Colitis: full overview → · 溃疡性结肠炎成本 → · Cost →
由 StemCellAtlas 的编辑团队进行医学审查，与Dr Polina Krasenova (Haematologist · Clinical Haematology & Integrative Oncology · 15+ yrs cell therapy) 合作诊所 Stem Plus（索菲亚）的，根据 ISSCR、FDA 和 EMA 指南。 Educational information, not medical advice; figures indicative.
位于欧盟核心的 GMP 认证再生医学诊所——费用 3,000–8,000 欧元起，仅为美国或德国价格的一小部分。为来自 50 多个国家的国际患者提供个性化方案。
免费医疗评估